THE SUBSTANCE
A biological glycosaminoglycan complex
Sulodexide is not one small uniform molecule. It is a purified glycosaminoglycan complex, commonly described as approximately 80% fast-moving heparin-like fraction and 20% dermatan sulfate. The heparin-like fraction shows affinity for antithrombin III; dermatan sulfate interacts with heparin cofactor II.
Its profile involves anticoagulant and antithrombotic pathways — and its published research extends into glycocalyx biology, vascular permeability, endothelial inflammatory signalling, fibrinolytic balance, nitric oxide, vascular relaxation, extracellular-matrix turnover, matrix metalloproteinases, microvascular function, renal filtration barriers, chronic venous disease and vascular injury following infection.
Sulodexide has been studied in oral and parenteral forms internationally; availability, authorisation and indications vary by country. This website is not a prescribing service and contains no dosage instructions.
A complex mixture, not a single entity
Because sulodexide is a complex biological mixture rather than one small uniform molecular entity, its characterisation — fraction proportions, molecular-weight distribution, charge, sulphation, potency — is a scientific question in its own right. That is one reason Panacea treats composition and analytical characterisation as a dedicated research pillar.
An international non-proprietary name
Sulodexide is an established international non-proprietary pharmaceutical substance. Panacea Bio Chem does not claim to have invented the original substance, does not claim ownership of it, and is not affiliated with its existing manufacturers. The Panacea programme is an independent investigation into its mechanisms, composition, formulation and future vascular-repair potential.
Why Panacea investigates it
The scientific interest lies at the interface: the glycocalyx, coagulation, fibrinolysis, inflammation and permeability are not isolated systems. Sulodexide’s two fractions touch several of them at once — which makes the complex a starting architecture for investigating the vascular interface as one molecular system.